Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Studies of structure-functional peculiarities of soluble Her2 secreted by breast tumor cells

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Yulia Trizna

Citation

Annals of Oncology (2015) 26 (suppl_9): 1-7. 10.1093/annonc/mdv517

Authors

Y.A. Trizna1, K.A. Glukhova1, A.S. Glukhov1, V.V. Marchenkov2, B. Melnik3, G.V. Afanasieva1, A.A. Ivanov4, O.P. Popova4, T.I. Danilova4, I.P. Beletsky1, O.V. Proussakova1

Author affiliations

  • 1 Laboratory Of Cell Engineering, Institute of Theoretical and Experimental Biophysics of RAS, 142290 - Pushchino/RU
  • 2 Laboratory Of Protein Physics, Institute of Protein Research of RAS, 142290 - Pushchino/RU
  • 3 Laboratory Of Protein Physics, IPR RAS, 142290 - Pushchino/RU
  • 4 Department Of Molecular Medicine, I.M.Sechenov First Moscow State Medical University, Moscow/RU
More

Resources

Abstract 932

Aim/Background

The role of soluble Her2 (sHer2) in Her2-dependent oncogenicity and in conditioning the response to HER2-mediated therapies has remained elusive. In such studies, the concentrations level of sHer2 and alternative splicing form(s) of Her2 in oncological patients are in the focus of attention. Both the oligomeric status of sHer2 generated by tumor cells and its possible prognostic value have not been examined so far. In this study we have tried to analyze the oligomeric status of sHer2 in breast cancer patients.

Methods

Recombinant human sHer2 produced by HEK 293 and sHer2 isolated from the supernatant of the primary tumor cell culture from breast cancer patients was used in the experiments. The oligomeric status was estimated using the method of gel-filtration chromatography and electrophoresis. The stability of Her2 was determined by the change in the protein secondary structure under variation of temperature and pH values by means of CD spectroscopy. The inhibitory activity of sHer2 was analyzed in tests with Her2-expressing cell cultures. The content of sHer2 in the supernatant of primary tumor cell cultures from breast cancer patients was determined using the sandwich ELISA. Amplification of the HER2 gene in the primary tumor cells was verified employing the FISH.

Results

The electrophoretic and chromatographic analyses show that sHer2 is present mostly as a tetramer capable of inhibiting proliferation of Her2-expressing cell cultures. sHer2 is stable upon heating the solution to 50°C in the pH range from 7 to 9. It should be noted that the high level of sHer2 is found in supernatants of the primary tumor cell cultures from breast cancer patients not only with amplified Her, but also in triple negative breast cancer samples (ER - 0; PR - 0; Her-2/neu negative (0 + 1); Ki 67 - 27 - 87%).

Conclusions

In our opinion, the results obtained show that the oligomeric status of sHer2 can be regarded as a prognostic factor. This work was supported by the grant from Ministry of Education and Science of the Russian Federation (№ 14.604.21.0025, ID RFMEFI60414X0025).

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings